CORDIS
EU research results

CORDIS
English EN

Immune profiling to guide host-directed interventions to cure HBV infections

Project information

Grant agreement ID: 847939

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2024

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 14 943 030,50

  • EU contribution

    € 9 983 029

Coordinated by:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

Project description

DE EN ES FR IT PL
English EN

Host-directed interventions to cure hepatitis B infections

The objective of the EU-funded IP-cure-B project is to develop novel curative concepts for chronic hepatitis B (CHB). The project aims to improve the cure rate of CHB by boosting innate immunity with immune modulators and stimulating adaptive immune responses with a novel therapeutic vaccine. Researchers will also identify immune and viral biomarkers for patient stratification and treatment response monitoring. Integration of biological and clinical data will enable models for the best combination treatment and effectiveness of novel curative therapies with respect to disease spectrum and patient heterogeneity. The preclinical platform will be evaluated in humanised mice, combining immune-modulatory strategies to stimulate innate immunity, rescue exhausted HBV-specific T cells and generate anti-HBV adaptive responses. Proof of concept will be obtained in a clinical trial of a combination of novel compounds stimulating innate immunity.

Programme(s)

H2020-EU.3.1.3. - Treating and managing disease

Topic(s)

SC1-BHC-14-2019 - Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases

Call for proposal

H2020-SC1-2019-Two-Stage-RTD

See other projects for this call

Funding Scheme

RIA - Research and Innovation action
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Address

Rue De Tolbiac 101
75654 Paris

France

Activity type

Research Organisations

EU Contribution

€ 4 094 578

Website

Contact the organisation

Participants (13)

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Switzerland

EU Contribution

€ 690 048

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 299 550

INSTITUT PASTEUR

France

EU Contribution

€ 1 593 800

UNIVERSITA DEGLI STUDI DI PARMA

Italy

EU Contribution

€ 1 030 053

FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO

Italy

EU Contribution

€ 250 000

UNIVERSITAETSKLINIKUM FREIBURG

Germany

EU Contribution

€ 850 000

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Greece

EU Contribution

€ 250 000

FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA

Spain

EU Contribution

€ 250 000

GILEAD SCIENCES INC

United States

SPRING BANK PHARMACEUTICALS INC.

United States

EUROPEAN LIVER PATIENTS ASSOCIATION

Belgium

EU Contribution

€ 175 000

INSERM TRANSFERT SA

France

EU Contribution

€ 300 000

HOSPICES CIVILS DE LYON

France

EU Contribution

€ 200 000

Project information

Grant agreement ID: 847939

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2024

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 14 943 030,50

  • EU contribution

    € 9 983 029

Coordinated by:

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

Download

PDF XML

Last update: 3 March 2020

Record number: 226451